Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)

This trial is testing the safety and effectiveness of Verity-BCG — a type of immunotherapy delivered directly into the bladder — in patients with non-muscle-invasive bladder cancer (cancer that hasn't grown into the bladder's muscle wall) who have never had BCG treatment before. **You may be eligible if...** - You are 18 or older with bladder cancer (stage Ta or T1) that has been completely removed by surgery - Your cancer has an intermediate or high risk of returning - You have never had BCG treatment in your bladder - Your kidney function, blood counts, and liver function are adequate - You are not pregnant and agree to use contraception **You may NOT be eligible if...** - Your cancer has spread to the upper urinary tract or prostate - You have only carcinoma-in-situ (CIS), squamous cell or glandular cancer - You have had BCG treatment before (except a childhood tuberculosis vaccine) - You have HIV or an impaired immune system - You have an active urinary tract infection - You are currently taking chronic steroids or undergoing other cancer therapies - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.